Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea FDA Unveils Initial Biosimilar Guidance; Final Guidelines To Be Released In July

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's FDA is putting the final touches on its EU-modeled initial guidelines for approval and registration of biosimilar products, and anticipates releasing a final version by the end of July

You may also be interested in...



Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar

Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.

Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar

Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.

Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade

Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.

Related Content

UsernamePublicRestriction

Register

SC072045

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel